Login to Your Account



Taurx AD drug only helps as mono, phase III shows

By Randy Osborne
Staff Writer

Wednesday, July 27, 2016

A site investigator in the failed phase III study by Taurx Therapeutics Ltd. told BioWorld Today that Alzheimer's disease "absolutely" will best be attacked by a combination approach.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription